All Janssen HME Forum webinars

What are the key drivers for selecting ideal RRMM patients for treatment with CAR T-cell therapy?

16 November 2022 - 46 Minutes

Faculty

Michel Delforge

Joaquin Martinez-Lopez

Hermann Einsele

EM-93624

A focus on standard risk patients with MM and the roadmap to cure

15 November 2022 - 44 Minutes

Faculty

Mohamad Mohty

Jesús San Miguel

EM-93617

INSIDER: Highlights from the 11th International Workshop on Waldenström’s Macroglobulinemia

9 November 2022 - 50 Minutes

Faculty

Christian Buske

Ramon Garcia-Sanz

Steve Treon

EM-96531

Challenges in CLL: Continuous, time-limited, or MRD-guided therapy

8 November 2022 - 46 Minutes

Faculty

Paolo Ghia

Talha Munir

José Carda

EM-92734

What are the key drivers for selecting ideal RRMM patients for treatment with bispecific antibodies?

25 October 2022 - 49 Minutes

Faculty

Michel Delforge

Paula Rodriguez Otero

Philippe Moreau

EM-93607

How do we ensure we choose the right treatment for the right patient?

4 October 2022 - 46 Minutes

Faculty

Mohamad Mohty

Faith Davies

Charlotte Pawlyn

EM-93604

Challenges in CLL: How risk stratification can guide the choice of first-line treatment in patients with CLL

13 September 2022 - 47 Minutes

Faculty

John Gribben

Carol Moreno

Ruth Clifford

Paolo Sportoletti

EM-93552

MRD - What will change in the next year?

5 July 2022 - 45 Minutes

Faculty

Mohamad Mohty

Fredrik Schjesvold

EM-93560

Highlights from EHA 2022: Expert insights and clinical implications for the management of patients with multiple myeloma

22 June 2022 - 64 Minutes

Faculty

María Victoria Mateos

Saad Zafar Usmani

Niels van de Donk

EM-93557

Challenges in CLL: how does the data from EHA 2022 inform key management questions?

21 June 2022 - 63 Minutes

Faculty

John Gribben

Paolo Ghia

EM-78442

1
2
3
4